Clinical Trial Update: Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of a protease activated receptor-4 antagonist for reducing recurrent strokes; trial completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombosis

Drugs mentioned

• Protease Activated Receptor-4 antagonist

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Thrombosis | Phase 2 | Status: COMPLETED | Results posted: 2018-06-12